Therapeutic Insights: HER1-Driven Immune Modulation in Pathological Progression and Disease Management of Oral Cavity Carcinomas
DOI:
https://doi.org/10.36283/ziun-pjmd14-4/042Keywords:
Carcinoma, Squamous Cell, Mouth Neoplasms, ErbB Receptors, Tumor Microenvironment, CD8-Positive T-LymphocytesAbstract
Background: Oral cavity carcinoma (OCC) is a virulent malignancy associated with a poor prognosis, typically presenting under immune evasion and further progression. The Human Epidermal Growth Factor Receptor 1 (HER1/EGFR) is involved in the progression of tumors and immune suppression in solid tumors. The objective of this study was to assess the HER1 expression and its correlations with tumor-infiltrating lymphocytes (CD8+, FOXP3+) and immunosuppressive cytokines (IL-6, TGF-beta) in OCC. Methods: This case-control study was conducted between January and June of 2025 at an oncology department. 150 OCC tissue samples were histologically confirmed, and 50 non-malignant controls were analyzed. Immunohistochemistry (IHC) was performed to identify HER1, CD8+, and FOXP3+ markers, whereas IL-6 and TGF-beta were measured by RT-qPCR. Tumors were stratified by HER1 positivity, and statistical tests were conducted using SPSS 26.0. t-Test and chi-square tests were utilized, and the significance level was set at p < 0.05. Results: Its overexpression was observed in 123 (82%) of OCC tumors (p <0.001) and strongly correlated with low CD8+, high FOXP3+, regulatory T cells, and high IL-6 and TGF-b concentrations (p < 0.001). In HER1-positive samples, the strongest immune suppression was observed in the case of advanced-stage tumors. Conclusion: In addition to being a growth-stimulatory oncogene, HER1 plays a central role in immune dysregulation in OCC. The results support HER1-directed treatments as a strategic resource to reverse immune escape and manage OCC patients.
References
1. Caponio VCA, Zhurakivska K, Lo Muzio L, Troiano G, Cirillo N. The Immune Cells in the Development of Oral Squamous Cell Carcinoma. Cancers (Basel). 2023 Jul 26;15(15):3779. doi: 10.3390/cancers15153779.
2. Nemati S, Islami F, Kamangar F, Poustchi H, Roshandel G, Shakeri R, et al. Improvement of esophageal cancer survival in Northeast Iran: A two-decade journey in a high-risk, low- resource region. PLoS One. 2024 Sep 25;19(9):e0310842. doi: 10.1371/journal.pone.0310842.
3. Cívico-Ortega JL, González-Ruiz I, Ramos-García P, Cruz-Granados D, Samayoa-Descamps V, González-Moles MÁ. Prognostic and Clinicopathological Significance of Epidermal Growth Factor Receptor (EGFR) Expression in Oral Squamous Cell Carcinoma: Systematic Review and Meta-Analysis. Int J Mol Sci. 2023 Jul 25;24(15):11888. doi: 10.3390/ijms241511888.
4. Elshazly AM, Gewirtz DA. An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer. Cancer Drug Resist. 2022 Jun 1;5(2):472-486. doi: 10.20517/cdr.2022.09.
5. Liu L, Wang C, Li S, Bai H, Wang J. Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review. Transl Lung Cancer Res. 2021 Sep;10(9):3823-3839. doi: 10.21037/tlcr-21-572.
6. Lequerica-Fernández P, Suárez-Canto J, Rodriguez-Santamarta T, Rodrigo JP, Suárez-Sánchez FJ, Blanco-Lorenzo V, et al. Prognostic Relevance of CD4+, CD8+ and FOXP3+ TILs in Oral Squamous Cell Carcinoma and Correlations with PD-L1 and Cancer Stem Cell Markers. Biomedicines. 2021 Jun 8;9(6):653. doi: 10.3390/biomedicines9060653.
7. Guo Y, Xu T, Chai Y, Chen F. TGF-β Signaling in Progression of Oral Cancer. Int J Mol Sci. 2023 Jun 17;24(12):10263. doi: 10.3390/ijms241210263.
8. Chakraborty R, Khodlan P, Tay A, Liu F. STAT3 interactome predicts presence of proteins that regulate immune system in oral squamous cell carcinoma. J Oral Biosci. 2024 Dec;66(4):67-73. doi: 10.1016/j.job.2024.09.002.
9. Chaudhary R, Slebos RJC, Noel LC, Song F, Poole MI, Hoening DS, et al. EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma. Cancer Res Commun. 2023 May 22;3(5):896-907. doi: 10.1158/2767-9764.CRC-22-0443.
10. Xue N, Wang Y, Wang Z, Zeng X, Wang J, Zhang X. Trends in immunotherapy for oral squamous cell carcinoma. Cell Oncol (Dordr). 2025 Jun 23. doi: 10.1007/s13402-025-01068-3.
11. Bhardwaj R, Agrawal U, Vashist P, Manna S. Determination of sample size for various study designs in medical research: A practical primer. J Family Med Prim Care. 2024 Jul;13(7):2555-2561. doi: 10.4103/jfmpc.jfmpc_1675_23.
12. Singh R, Song S. Clinical outcomes following observation, post-operative radiation therapy, or post-operative chemoradiation for HPV-associated oropharyngeal squamous cell carcinomas. Oral Oncol. 2023 Nov;146:106493. doi: 10.1016/j.oraloncology.2023.106493.
13. Xie G, Shan L, Liu Y, Wu TC, Gu X. Antitumor Efficacy of EGFR-Targeted Recombinant Immunotoxin in Human Head and Neck Squamous Cell Carcinoma. Biology (Basel). 2022 Mar 22;11(4):486. doi: 10.3390/biology11040486.
14. Alonso-Juarranz M, Mascaraque M, Carrasco E, Gracia-Cazaña T, De La Sen O, Gilaberte Y, Gonzalez S, et al. The Distinctive Features behind the Aggressiveness of Oral and Cutaneous Squamous Cell Carcinomas. Cancers (Basel). 2023 Jun 17;15(12):3227. doi: 10.3390/cancers15123227.
15. Elmusrati A, Wang J, Wang CY. Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int J Oral Sci. 2021 Aug 2;13(1):24. doi: 10.1038/s41368-021-00131-7.
16. Wongpattaraworakul W, Gibson-Corley KN, Choi A, Buchakjian MR, Lanzel EA, Rajan Kd A, et al. Prognostic Role of Combined EGFR and Tumor-Infiltrating Lymphocytes in Oral Squamous Cell Carcinoma. Front Oncol. 2022 Jul 25;12:885236. doi: 10.3389/fonc.2022.885236.
17. Kerneur C, Cano CE, Olive D. Major pathways involved in macrophage polarization in cancer. Front Immunol. 2022 Oct 17;13:1026954. doi: 10.3389/fimmu.2022.1026954.
18. Guazzo E, Cooper C, Wilkinson L, Feng S, King B, Simpson F, et al. Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma. Head Neck. 2021 Mar;43(3):768-777. doi: 10.1002/hed.26529.
19. Li C, Guo H, Zhai P, Yan M, Liu C, Wang X, et al. Spatial and Single-Cell Transcriptomics Reveal a Cancer-Associated Fibroblast Subset in HNSCC That Restricts Infiltration and Antitumor Activity of CD8+ T Cells. Cancer Res. 2024 Jan 16;84(2):258-275. doi: 10.1158/0008-5472.CAN-23-1448.
20. Chai AWY, Yee PS, Cheong SC. Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers. Front Oncol. 2022 Mar 17;12:837835. doi: 10.3389/fonc.2022.837835.
21. Li J, Xiao Y, Yu H, Jin X, Fan S, Liu W. Mutual connected IL-6, EGFR and LIN28/Let7-related mechanisms modulate PD-L1 and IGF upregulation in HNSCC using immunotherapy. Front Oncol. 2023 Apr 12;13:1140133. doi: 10.3389/fonc.2023.1140133.
22. Gao A, Pan X, Yang X, Lin Z. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors. Invest New Drugs. 2021 Aug;39(4):1132-1138. doi: 10.1007/s10637-021-01082-w.
23. Qi Z, Qiu Y, Wang Z, Zhang H, Lu L, Liu Y, et al. A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma. Mol Oncol. 2021 Apr;15(4):1054-1068. doi: 10.1002/1878-0261.12919.
24. Chaudhary R, Slebos RJC, Noel LC, Song F, Poole MI, Hoening DS, et al. EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma. Cancer Res Commun. 2023 May 22;3(5):896-907. doi: 10.1158/2767-9764.CRC-22-0443.
25. Britton WR, Cioffi I, Stonebraker C, Spence M, Okolo O, Martin C, et al. Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2024 Aug 31;16(17):3047. doi: 10.3390/cancers16173047.
26. Castiglioni A, Yang Y, Williams K, Gogineni A, Lane RS, Wang AW, et al. Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors. Nat Commun. 2023 Aug 5;14(1):4703. doi: 10.1038/s41467-023-40398-4.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
